Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses MNKD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MNKD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Castagna | $789,436 | $0 | $7,689,480 | $0 | $675,757 | $0 | $145,812 | $9,300,485 |
| Chief Executive Officer | ||||||||
| Dominic Marasco | 447,596 | 0 | 6,269,015 | 0 | 239,464 | 0 | 24,397 | 6,980,472 |
| President, Endocrine Business Unit | ||||||||
| David Thomson | 520,748 | 0 | 2,133,480 | 0 | 378,600 | 0 | 122,420 | 3,155,248 |
| Executive Vice President, General Counsel and Secretary | ||||||||
| Stuart Tross | 438,709 | 0 | 2,133,480 | 0 | 234,709 | 0 | 138,797 | 2,945,695 |
| Executive Vice President, Human Resources | ||||||||
| Christopher Prentiss | 470,085 | 0 | 2,133,480 | 0 | 251,495 | 0 | 31,739 | 2,886,799 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Castagna | $9,300,485 | — | — | — |
| Dominic Marasco | 6,980,472 | — | — | — |
| David Thomson | 3,155,248 | — | — | — |
| Stuart Tross | 2,945,695 | — | — | — |
| Christopher Prentiss | 2,886,799 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christopher Prentiss | Chief Financial Officer | 2026-04-22 | D | 12,267 | $3 | $33,612 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-05-11 | D | 16,940 | 3 | 55,733 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-05-11 | D | 34,957 | 4 | 123,049 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-05-11 | D | 3,033 | 3 | 9,979 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-05-11 | D | 8,073 | 4 | 28,417 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-05-11 | D | 5,560 | 4 | 19,571 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-05-11 | D | 12,387 | 4 | 43,602 | Common | Form 4 ↗ |
| Christine Mundkur | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony Hooper | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dominic Marasco | Pres, Endocrine Business Unit | 2026-05-20 | A | 8,474 | 3 | 24,998 | Common | Form 4 ↗ |
| Ronald J. Consiglio | Director | 2026-05-20 | A | 16,556 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James S. Shannon | Director | 2026-05-20 | A | 16,556 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-05-20 | A | 33,898 | 3 | 99,999 | Common | Form 4 ↗ |
| Jennifer Grancio | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael A. Friedman | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald J. Consiglio | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony Hooper | Director | 2026-05-20 | A | 16,556 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sabrina Kay | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald J. Consiglio | Director | 2026-05-20 | A | 10,000 | 3 | 29,500 | Common | Form 4 ↗ |
| James S. Shannon | Director | 2026-05-20 | A | 82,781 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | A | 93,790 | 0 | 0 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | D | 93,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | D | 4,073 | 4 | 16,659 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 93,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | D | 8,253 | 4 | 33,755 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | D | 63,996 | 4 | 261,744 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | D | 15,688 | 4 | 64,164 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | D | 52,485 | 4 | 213,089 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | A | 350,260 | 0 | 0 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | D | 12,331 | 4 | 50,434 | Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | A | 70,550 | 0 | 0 | Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | D | 5,372 | 4 | 21,971 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 12,662 | 4 | 51,788 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | A | 93,790 | 0 | 0 | Common | Form 4 ↗ |
| Dominic Marasco | Pres, Endocrine Business Unit | 2026-07-15 | D | 3,623 | 4 | 14,818 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | D | 11,572 | 4 | 47,329 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | D | 4,634 | 4 | 18,953 | Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | D | 22,047 | 4 | 90,172 | Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | D | 70,550 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 24,109 | 4 | 97,641 | Common | Form 4 ↗ |
| Christopher Prentiss | Chief Financial Officer | 2026-07-15 | D | 11,572 | 4 | 47,329 | Common | Form 4 ↗ |
| Christopher Prentiss | Chief Financial Officer | 2026-07-15 | D | 10,675 | 4 | 43,661 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | A | 93,790 | 0 | 0 | Common | Form 4 ↗ |
| Stuart Tross | Chief People & Workpl Officer | 2026-07-15 | D | 33,652 | 4 | 137,637 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | D | 192,819 | 4 | 788,630 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | D | 47,481 | 4 | 194,197 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | D | 58,904 | 4 | 240,917 | Common | Form 4 ↗ |
| Michael Castagna | Director | 2026-07-15 | D | 350,260 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | D | 10,079 | 4 | 41,223 | Common | Form 4 ↗ |
| Sanjay R. Singh | EVP Technical Operations | 2026-07-15 | D | 9,297 | 4 | 38,025 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 51,632 | 4 | 211,175 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 17,754 | 4 | 72,614 | Common | Form 4 ↗ |
| David Thomson | EVP Genl Counsel & Secretary | 2026-07-15 | D | 16,378 | 4 | 66,986 | Common | Form 4 ↗ |
| Steven B. Binder | Director | 2026-07-15 | D | 93,790 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Christopher Prentiss | PRSU | — | — | — | — | — | $2,133,480 |
| Dominic Marasco | PRSU | — | — | — | — | — | 6,269,015 |
| Stuart Tross | PRSU | — | — | — | — | — | 2,133,480 |
| David Thomson | PRSU | — | — | — | — | — | 2,133,480 |
| Michael Castagna | PRSU | — | — | — | — | — | 7,689,480 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stuart Tross | PSU | 145,000 | — | $822,150 |
| David Thomson | PSU | 113,000 | — | 640,710 |
| Dominic Marasco | RSU | 59,500 | — | 337,365 |
| Michael Castagna | RSU | 348,750 | — | 1,977,413 |
| Stuart Tross | RSU | 46,000 | — | 260,820 |
| David Thomson | RSU | 46,000 | — | 260,820 |
| Christopher Prentiss | RSU | 103,600 | — | 587,412 |
| Michael Castagna | PSU | 523,000 | — | 2,965,410 |
| Michael Castagna | PSU | 422,000 | — | 2,392,740 |
| Michael Castagna | PSU | 569,000 | — | 3,226,230 |
| Michael Castagna | RSU | 428,000 | — | 2,426,760 |
| Christopher Prentiss | PSU | 158,000 | — | 895,860 |
| Michael Castagna | RSU | 63,500 | — | 360,045 |
| Dominic Marasco | PSU | 1,000,000 | — | 5,670,000 |
| Dominic Marasco | PSU | 72,500 | — | 411,075 |
| Stuart Tross | PSU | 158,000 | — | 895,860 |
| David Thomson | PSU | 145,000 | — | 822,150 |
| David Thomson | PSU | 158,000 | — | 895,860 |
| Christopher Prentiss | PSU | 145,000 | — | 822,150 |
| Christopher Prentiss | RSU | 119,000 | — | 674,730 |
| Christopher Prentiss | RSU | 96,750 | — | 548,573 |
| David Thomson | RSU | 22,500 | — | 127,575 |
| David Thomson | RSU | 119,000 | — | 674,730 |
| Stuart Tross | RSU | 119,000 | — | 674,730 |
| Stuart Tross | PSU | 113,000 | — | 640,710 |
| Stuart Tross | RSU | 96,750 | — | 548,573 |
| David Thomson | RSU | 96,750 | — | 548,573 |
| Stuart Tross | RSU | 22,500 | — | 127,575 |
| Dominic Marasco | RSU | 252,000 | — | 1,428,840 |
| Michael Castagna | RSU | 172,500 | — | 978,075 |
This philosophy is to provide compensation and benefits programs designed to attract, engage, and retain a high caliber workforce that enables us to compete with companies in the pharmaceutical and biotechnology industries and to reward individual and corporate performance.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer LLC |
| Clawback policy | True |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 137,332,418 | 16,295,138 | 1,303,497 | 89.39% | Passed |
| 2025 | 2025-05-14 | 131,379,082 | 11,526,793 | 1,338,683 | 91.93% | Passed |
| 2024 | 2024-05-15 | 112,281,517 | 11,612,528 | 1,260,654 | 89.71% | Passed |
| 2023 | 2023-05-25 | 113,431,647 | 11,361,302 | 1,048,616 | 90.9% | Passed |
| 2022 | 2022-05-10 | 78,653,564 | 9,044,501 | 1,224,148 | 88.45% | Passed |
| 2021 | 2021-05-20 | 83,582,134 | 7,850,095 | 1,293,441 | 90.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-20 | 89.39%a |
| 2025 | 2025-05-14 | 91.93%b |
| 2024 | 2024-05-15 | 89.71%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will be counted toward the tabulation of votes cast on the proposal and will have the same effect as "Against" votes.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 46 : 1 |
|---|---|
| CEO total compensation | $9,300,485 |
| Median employee compensation | $203,592 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James S. ShannonIndependent · Board Chair · Compensation | $80,000 | $241,543 | $0 | $0 | $0 | $321,543 |
| Ronald J. ConsiglioIndependent · Audit (Chair) · Nominating and Corporate Governance | 80,000 | 241,543 | 0 | 0 | 0 | 321,543 |
| Anthony HooperIndependent · Compensation (Chair) · Audit · Newly elected | 30,000 | 289,852 | 0 | 0 | 0 | 319,852 |
| Jennifer GrancioIndependent · Nominating and Corporate Governance (Chair) · Audit | 70,000 | 241,543 | 0 | 0 | 0 | 311,543 |
| Sabrina KayIndependent · Compensation · Audit · Newly elected | 17,500 | 289,852 | 0 | 0 | 0 | 307,352 |
| Christine MundkurIndependent · Audit · Nominating and Corporate Governance | 65,000 | 241,543 | 0 | 0 | 0 | 306,543 |
| Michael A. FriedmanIndependent · Nominating and Corporate Governance | 55,000 | 241,543 | 0 | 0 | 0 | 296,543 |
| Steven B. BinderNot independent | 50,000 | 241,543 | 0 | 0 | 0 | 291,543 |
| Michael E. CastagnaEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $241,543 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $447,500 |
| Equity awards (grant-date value) | $2,028,962 |
| All other compensation | $0 |
| Total cost of the board | $2,476,462 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies MannKind names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including MannKind.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ADMA Biologics, Inc. | 2025 | Adam Grossman | $925,000 | $4,049,994 | $4,049,998 | $1,156,250 | $10,237,326 |
| 2 | MannKind | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 3 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| MannKind | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| ADMA Biologics, Inc. | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Castagna | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Compensation Table”. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621 |
| 2 | Section 01, Dominic Marasco | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Compensation Table”. As printed: 6,980,472. Filing ↗machine: t24 · r12 · c27 · span 673006–673015 |
| 3 | Section 01, David Thomson | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Compensation Table”. As printed: 3,155,248. Filing ↗machine: t24 · r15 · c27 · span 698680–698689 |
| 4 | Section 01, Stuart Tross | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Compensation Table”. As printed: 2,945,695. Filing ↗machine: t24 · r19 · c27 · span 736983–736992 |
| 5 | Section 01, Christopher Prentiss | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Compensation Table”. As printed: 2,886,799. Filing ↗machine: t24 · r9 · c27 · span 644922–644931 |
| 6 | Section 03, Christopher Prentiss PRSU | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t24 · r9 · c12 · span 639729–639738 |
| 7 | Section 03, Dominic Marasco PRSU | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t24 · r12 · c12 · span 667815–667824 |
| 8 | Section 03, Stuart Tross PRSU | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t24 · r19 · c12 · span 731751–731760 |
| 9 | Section 03, David Thomson PRSU | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t24 · r15 · c12 · span 693487–693496 |
| 10 | Section 03, Michael Castagna PRSU | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t24 · r5 · c12 · span 601417–601426 |
| 11 | Section 07, pay ratio | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “CEO Pay Ratio”. As printed: 46 : 1. Filing ↗machine: span 1491900–1491902 |
| 12 | Section 08, James S. Shannon | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 321,543. Filing ↗ |
| 13 | Section 08, Ronald J. Consiglio | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 321,543. Filing ↗machine: t14 · r3 · c8 · span 313189–313196 |
| 14 | Section 08, Anthony Hooper | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 319,852. Filing ↗machine: t14 · r6 · c8 · span 323832–323839 |
| 15 | Section 08, Jennifer Grancio | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 311,543. Filing ↗machine: t14 · r5 · c8 · span 320284–320291 |
| 16 | Section 08, Sabrina Kay | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 307,352. Filing ↗machine: t14 · r7 · c8 · span 327377–327384 |
| 17 | Section 08, Christine Mundkur | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 306,543. Filing ↗machine: t14 · r8 · c8 · span 330924–330931 |
| 18 | Section 08, Michael A. Friedman | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 296,543. Filing ↗machine: t14 · r4 · c8 · span 316738–316745 |
| 19 | Section 08, Steven B. Binder | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 291,543. Filing ↗machine: t14 · r2 · c8 · span 309640–309647 |
| 20 | Section 08, Michael E. Castagna | DEF 14A | 2026-04-07 | 0001193125-26-145613 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 02, Christopher Prentiss 2026-04-22 | Form 4 | 2026-04-24 | 0001193125-26-178298 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Steven B. Binder 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222311 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Michael Castagna 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222309 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, David Thomson 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Stuart Tross 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222312 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Steven B. Binder 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222311 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, David Thomson 2026-05-11 | Form 4 | 2026-05-13 | 0001193125-26-222310 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Christine Mundkur 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237426 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Steven B. Binder 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237438 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Anthony Hooper 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237431 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Dominic Marasco 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237428 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Ronald J. Consiglio 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237444 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, James S. Shannon 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237430 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Stuart Tross 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237429 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Jennifer Grancio 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237432 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Michael A. Friedman 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237456 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Ronald J. Consiglio 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237444 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Anthony Hooper 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237431 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Sabrina Kay 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237424 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Ronald J. Consiglio 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237444 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, James S. Shannon 2026-05-20 | Form 4 | 2026-05-22 | 0001193125-26-237430 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Dominic Marasco 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308137 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Christopher Prentiss 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Christopher Prentiss 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Stuart Tross 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308134 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Michael Castagna 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308133 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Sanjay R. Singh 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308132 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, David Thomson 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Steven B. Binder 2026-07-15 | Form 4 | 2026-07-17 | 0001193125-26-308129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 06, 2026 vote | Form 8-K | 2026-05-22 | 0001193125-26-237183 | Item 5.07 · say-on-pay result. As reported: 89.39% (votes for as printed: 137,332,418). Filing ↗ |
| 77 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0000950170-25-074523 | Item 5.07 · say-on-pay result. As reported: 91.93% (votes for as printed: 131,379,082). Filing ↗ |
| 78 | Section 06, 2024 vote | Form 8-K | 2024-05-16 | 0000950170-24-061164 | Item 5.07 · say-on-pay result. As reported: 89.71% (votes for as printed: 112,281,517). Filing ↗ |
| 79 | Section 09b board cost (computed) | Computed | — | computed | Cash 447,500 + equity 2,028,962 + all other 0 = 2,476,462, summed across the director compensation table rows.machine: formula: Σ = 2,476,462 |
| 80 | ADMA Biologics, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001140361-26-014799 | CEO total compensation as printed in ADMA Biologics, Inc.'s own proxy. As printed: 10,237,326. Filing ↗machine: r2 · c25 · span 619659–619670 |
| 81 | MannKind (subject), Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145613 | CEO total compensation as printed in MannKind's own proxy. As printed: 9,300,485. Filing ↗machine: t24 · r5 · c27 · span 606612–606621 |
| 82 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 83 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include MannKind. Filing ↗ |
| 84 | Section 10a, ADMA Biologics, Inc. reciprocity | DEF 14A | — | 0001140361-26-014799 | ADMA Biologics, Inc. names MannKind in its own disclosed peer group (read from its most recent proxy). Filing ↗ |